Background: Transurethral resection of prostate (TURP) is the gold standard in the surgical treatment of symptomatic benign prostatic hyperplasia (BPH). Blood loss is one of the most common complications of TURP. Obje...Background: Transurethral resection of prostate (TURP) is the gold standard in the surgical treatment of symptomatic benign prostatic hyperplasia (BPH). Blood loss is one of the most common complications of TURP. Objective: To evaluate the effect of preoperative dutasteride on bleeding related to TURP in patients with BPH. Materials and Methods: This prospective interventional study was done in the department of urology, Dhaka Medical College Hospital, Dhaka, Bangladesh during the period of July 2016 to June 2017. A total of 70 cases of BPH planned for TURP were included in this study according to the statistical calculation. Patients were randomly allocated to control group A (TURP without dutasteride) and dutasteride group B (TURP with dutasteride). Each group consisted of 35 patients. Group B patients were treated with dutasteride 0.5 mg/day for 4 weeks before TURP. The main outcome of blood loss was evaluated in terms of reduction in serum hemoglobin (Hb) and hematocrit (Hct) levels, which were measured before and 24 hours after surgery. Data were analyzed and compared by statistical tests. Results: Comparison of outcome between groups shows that there was a significant difference in term of pre-post operative change of hemoglobin and hematocrit levels in the control group A compared to the dutasteride group B (Hb = 2.96 ± 0.80 gm/dl vs. 1.81 ± 0.71 gm/dl, respectively, p = 0.001;Hct = 11.20% ± 2.12% vs. 6.07% ± 2.02%, respectively, p = 0.02). A significant lower mean blood loss was observed in the dutasteride group compared to the control group. Conclusion: Preoperative dutasteride therapy reduces blood loss related to TURP in patients with BPH. This therapy can be practiced to reduce surgical bleeding associated with TURP.展开更多
Transurethral resection of the prostate (TURP) is considered as the gold standard for the management of bladder outlet obstruction due to benign prostatic hyperplasia (BPH). Long-term follow-up of the clinical effect ...Transurethral resection of the prostate (TURP) is considered as the gold standard for the management of bladder outlet obstruction due to benign prostatic hyperplasia (BPH). Long-term follow-up of the clinical effect of bipolar transurethral resection of the prostate (B-TURP) in saline for BPH is required. Objective: To compare, with long term follow-up, the efficacy and safety of B-TURP in the treatment of BPH with prostate gland volumes of 45 ml, and larger than 60 ml. Materials and Methods: From January 2006 to December 2016, 318 patients with a mean age of 69.45 ± 8.37 years and a median prostate volume of 42 cm3 (56.51 - 32.47) were treated with B-TURP by single urologist (SP) at the Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University. We retrospectively analyzed the perioperative status of patients’ status follow-up for at least 6 months and up to 5 years. Post-void residual (PVR) and maximum flow rate (Qmax) were assessed preoperatively and postoperatively. Operative time, length of catheterization and hospitalization and complications were all reported. Results: The main indication for B-TURP was failure of medication (81.13%). Perioperative results showed no statistical significance among the groups in terms of catheterization days and the hospitalization length. During the follow-up, the improvement of postoperative parameters was compared with preoperative subscales, at different periods from baseline and after 24, 36, 48, and 60 months post treatment. PSA, Q max, PVR, and average flow rate were significantly different from pre-operation data (p Conclusion: With long-term follow-up, B-TURP is a safe and effective technique for BPH management with prostate gland 45 ml and larger than 60 ml.展开更多
Objective To assess the face and construct validity of a full procedural transurethral prostate resection simulator ( TURPSimTM ) in training of transurethral resection of prostate. Methods Ten experienced and thirtee...Objective To assess the face and construct validity of a full procedural transurethral prostate resection simulator ( TURPSimTM ) in training of transurethral resection of prostate. Methods Ten experienced and thirteen inexperienced urologists ( TURP experience ≥ 30 and展开更多
Objective： It is recommended that transurethral resection of the prostate （TURP） after brachytherapy should not be performed at an early stage after implantation. Herein we report our experiences and the results of...Objective： It is recommended that transurethral resection of the prostate （TURP） after brachytherapy should not be performed at an early stage after implantation. Herein we report our experiences and the results of channel TURP （cTURP） within six months post-implant for patients with refractory urinary retention. Methods： One hundred and ninety patients with localized prostate cancer of clinical stages Tlc to T2c were treated by brachytherapy as monotherapy at our institution from February 2009 to July 2013. Nine patients who developed refractory urinary retention and underwent cTURP within six months after brachytherapy were retrospectively reviewed and analyzed. Results： The median interval between prostate brachytherapy and cTURP was three months （range 1.5 to 5.0 months） There were no intraoperative or postoperative complications and no incontinence resulting from the surgery. All urinary retention was relieved per the American Brachytherapy Society urinary symptom score. With a mean follow-up time of 16 months （range 6 to 26 months） after cTURP, no patient experienced biochemical recurrence. The mean serum prostate-specific antigen （PSA） of the patients who underwent cTURP was 0.42 ng/ml （range 0.08 to 0.83 ng/ml） at the end of their follow-up. Conclusions： Early cTURP was found to be safe and effective in relieving urinary retention after brachytherapy and could be performed without compromising its therapeutic efficacy.展开更多
目的：分析经尿道前列腺电切（transurethral resection of prostate，TURP）术后前列腺偶发癌（incidental carcinoma of the prostate gland，ICPG）的治疗方法和随访结果。方法：对2001年1月-2006年12月532例TURP治疗患者的临床资料...目的：分析经尿道前列腺电切（transurethral resection of prostate，TURP）术后前列腺偶发癌（incidental carcinoma of the prostate gland，ICPG）的治疗方法和随访结果。方法：对2001年1月-2006年12月532例TURP治疗患者的临床资料进行回顾性分析。术后病理检出前列腺腺癌32例，18例行去势治疗，14例观察等待。对比术后病理诊断为前列腺癌的患者与前列腺增生的患者的前列腺抗原。结果：PSA值〈4ug/ml的390例患者中，前列腺腺癌检出率5．38％；PSA值4～10ug／ml的142例患者中，检出率7．75％，二者差异无统计学意义（X^2=1．28，P〉0．05）。29例获随访，随访19～86个月，平均（65．3±32．6）个月，3例失访。治疗组12例无瘤存活，观察组4例无瘤存活。观察等待与去势治疗患者的无瘤生存率之间差异有统计学意义（X^2=5．306，P〈0．05）。结论：PSA值对于前列腺偶发癌的预测作用不可靠，去势治疗可减轻偶发前列腺癌患者临床进展。展开更多
文摘Background: Transurethral resection of prostate (TURP) is the gold standard in the surgical treatment of symptomatic benign prostatic hyperplasia (BPH). Blood loss is one of the most common complications of TURP. Objective: To evaluate the effect of preoperative dutasteride on bleeding related to TURP in patients with BPH. Materials and Methods: This prospective interventional study was done in the department of urology, Dhaka Medical College Hospital, Dhaka, Bangladesh during the period of July 2016 to June 2017. A total of 70 cases of BPH planned for TURP were included in this study according to the statistical calculation. Patients were randomly allocated to control group A (TURP without dutasteride) and dutasteride group B (TURP with dutasteride). Each group consisted of 35 patients. Group B patients were treated with dutasteride 0.5 mg/day for 4 weeks before TURP. The main outcome of blood loss was evaluated in terms of reduction in serum hemoglobin (Hb) and hematocrit (Hct) levels, which were measured before and 24 hours after surgery. Data were analyzed and compared by statistical tests. Results: Comparison of outcome between groups shows that there was a significant difference in term of pre-post operative change of hemoglobin and hematocrit levels in the control group A compared to the dutasteride group B (Hb = 2.96 ± 0.80 gm/dl vs. 1.81 ± 0.71 gm/dl, respectively, p = 0.001;Hct = 11.20% ± 2.12% vs. 6.07% ± 2.02%, respectively, p = 0.02). A significant lower mean blood loss was observed in the dutasteride group compared to the control group. Conclusion: Preoperative dutasteride therapy reduces blood loss related to TURP in patients with BPH. This therapy can be practiced to reduce surgical bleeding associated with TURP.
文摘Transurethral resection of the prostate (TURP) is considered as the gold standard for the management of bladder outlet obstruction due to benign prostatic hyperplasia (BPH). Long-term follow-up of the clinical effect of bipolar transurethral resection of the prostate (B-TURP) in saline for BPH is required. Objective: To compare, with long term follow-up, the efficacy and safety of B-TURP in the treatment of BPH with prostate gland volumes of 45 ml, and larger than 60 ml. Materials and Methods: From January 2006 to December 2016, 318 patients with a mean age of 69.45 ± 8.37 years and a median prostate volume of 42 cm3 (56.51 - 32.47) were treated with B-TURP by single urologist (SP) at the Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University. We retrospectively analyzed the perioperative status of patients’ status follow-up for at least 6 months and up to 5 years. Post-void residual (PVR) and maximum flow rate (Qmax) were assessed preoperatively and postoperatively. Operative time, length of catheterization and hospitalization and complications were all reported. Results: The main indication for B-TURP was failure of medication (81.13%). Perioperative results showed no statistical significance among the groups in terms of catheterization days and the hospitalization length. During the follow-up, the improvement of postoperative parameters was compared with preoperative subscales, at different periods from baseline and after 24, 36, 48, and 60 months post treatment. PSA, Q max, PVR, and average flow rate were significantly different from pre-operation data (p Conclusion: With long-term follow-up, B-TURP is a safe and effective technique for BPH management with prostate gland 45 ml and larger than 60 ml.
文摘Objective To assess the face and construct validity of a full procedural transurethral prostate resection simulator ( TURPSimTM ) in training of transurethral resection of prostate. Methods Ten experienced and thirteen inexperienced urologists ( TURP experience ≥ 30 and
文摘Objective： It is recommended that transurethral resection of the prostate （TURP） after brachytherapy should not be performed at an early stage after implantation. Herein we report our experiences and the results of channel TURP （cTURP） within six months post-implant for patients with refractory urinary retention. Methods： One hundred and ninety patients with localized prostate cancer of clinical stages Tlc to T2c were treated by brachytherapy as monotherapy at our institution from February 2009 to July 2013. Nine patients who developed refractory urinary retention and underwent cTURP within six months after brachytherapy were retrospectively reviewed and analyzed. Results： The median interval between prostate brachytherapy and cTURP was three months （range 1.5 to 5.0 months） There were no intraoperative or postoperative complications and no incontinence resulting from the surgery. All urinary retention was relieved per the American Brachytherapy Society urinary symptom score. With a mean follow-up time of 16 months （range 6 to 26 months） after cTURP, no patient experienced biochemical recurrence. The mean serum prostate-specific antigen （PSA） of the patients who underwent cTURP was 0.42 ng/ml （range 0.08 to 0.83 ng/ml） at the end of their follow-up. Conclusions： Early cTURP was found to be safe and effective in relieving urinary retention after brachytherapy and could be performed without compromising its therapeutic efficacy.
文摘目的：分析经尿道前列腺电切（transurethral resection of prostate，TURP）术后前列腺偶发癌（incidental carcinoma of the prostate gland，ICPG）的治疗方法和随访结果。方法：对2001年1月-2006年12月532例TURP治疗患者的临床资料进行回顾性分析。术后病理检出前列腺腺癌32例，18例行去势治疗，14例观察等待。对比术后病理诊断为前列腺癌的患者与前列腺增生的患者的前列腺抗原。结果：PSA值〈4ug/ml的390例患者中，前列腺腺癌检出率5．38％；PSA值4～10ug／ml的142例患者中，检出率7．75％，二者差异无统计学意义（X^2=1．28，P〉0．05）。29例获随访，随访19～86个月，平均（65．3±32．6）个月，3例失访。治疗组12例无瘤存活，观察组4例无瘤存活。观察等待与去势治疗患者的无瘤生存率之间差异有统计学意义（X^2=5．306，P〈0．05）。结论：PSA值对于前列腺偶发癌的预测作用不可靠，去势治疗可减轻偶发前列腺癌患者临床进展。
